Dateline City:
LONDON & KENILWORTH, N.J.
Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab)
LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced
the initiation of a phase I clinical trial designed to evaluate GSKs
investigational immunotherapy GSK3174998 as monotherapy and in
combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab)
in patients with locally advanced, recurrent or metastatic solid
tumour(s) that have progressed after standard treatment.
Language:
English
Contact:
MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more